Matthew H. Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthew H. Wong has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Bob T. Li
Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication N. Pavlakis
Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia
1 shared publication- Nick Pavlakis
Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia
1 shared publication
Latest Publications
- Open Access
- 9 January 2014
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 3 (1) , 1-24
Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice
Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer are associated with skeletal-related events (SREs) including pathological fractures, spinal cord compression, surgery and radiotherapy to bone, as well as bone pain and hypercalcemia, leading to impaired mobility and reduced quality of life. Greater understanding of the pathophysiology of bone metastases has led to the discovery and clinical utility of bone-targeted agents such as bisphosphonates and the receptor activator of nuclear factor kappa-B ligand (RANK-L) antibody, denosumab. Both are now a routine part of the treatment of breast cancer bone metastases to reduce SREs. With regards to prevention, there is no evidence that oral bisphosphonates can prevent bone metastases in advanced breast cancer without skeletal involvement. Several phase III clinical trials have evaluated bisphosphonates as adjuvant therapy in early breast cancer to prevent bone metastases. The current published data do not support the routine use of bisphosphonates in unselected patients with early breast cancer for metastasis prevention. However, significant benefit of adjuvant bisphosphonates has been consistently observed in the postmenopausal or ovarian suppression subgroup across multiple clinical trials, which raises the hypothesis that its greatest anti-tumor effect is in a low estrogen microenvironment. An individual patient data meta-analysis will be required to confirm survival benefit in this setting. This review summarizes the key evidence for current clinical practice and future directions.
- 9 January 2014
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 3 (1) , 1-24
Open AccessTreatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice
Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer are associated with skeletal-related events (SREs) including pathological fractures, spinal cord compression, surgery and radiotherapy to bone, as well as bone pain and hypercalcemia, leading to impaired mobility and reduced quality of life. Greater understanding of the pathophysiology of bone metastases has led to the discovery and clinical utility of bone-targeted agents such as bisphosphonates and the receptor activator of nuclear factor kappa-B ligand (RANK-L) antibody, denosumab. Both are now a routine part of the treatment of breast cancer bone metastases to reduce SREs. With regards to prevention, there is no evidence that oral bisphosphonates can prevent bone metastases in advanced breast cancer without skeletal involvement. Several phase III clinical trials have evaluated bisphosphonates as adjuvant therapy in early breast cancer to prevent bone metastases. The current published data do not support the routine use of bisphosphonates in unselected patients with early breast cancer for metastasis prevention. However, significant benefit of adjuvant bisphosphonates has been consistently observed in the postmenopausal or ovarian suppression subgroup across multiple clinical trials, which raises the hypothesis that its greatest anti-tumor effect is in a low estrogen microenvironment. An individual patient data meta-analysis will be required to confirm survival benefit in this setting. This review summarizes the key evidence for current clinical practice and future directions.
- Open Access
- 1 May 2011
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. 3, 35-60
Optimal management of bone metastases in breast cancer patients
Peer reviewed article authored by (Wong MH, Pavlakis N). Read article or submit your manuscript for publishing.
- 1 May 2011
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. 3, 35-60
Open AccessOptimal management of bone metastases in breast cancer patients
Peer reviewed article authored by (Wong MH, Pavlakis N). Read article or submit your manuscript for publishing.